DelveInsight’s “Nausea and Vomiting Induced by Motion Sickness – Market Insight, Epidemiology And Market Forecast – 2032” report delivers comprehensive insights into the historical and projected epidemiology as well as the motion sickness market trends across the 7MM, which include the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
The motion sickness treatment market, valued at approximately USD 800 million in 2022, is expected to grow at a decent CAGR during the forecast period (2023- 2032). This growth trajectory is primarily attributed to expanding modes of transportation, increased recognition of symptoms, and forthcoming novel therapeutic solutions addressing the current limitations of existing treatments.
According to DelveInsight’s analysis, the US claimed the largest motion sickness market share in 2022, accounting for approximately USD 526 million, while EU4 and the UK together generated revenue of USD 175 million during the same period. This regional dominance reflects both higher prevalence and greater awareness of motion sickness management options in these regions.
Download the Stargardt Disease Market report to understand which factors are driving the Stargardt Disease therapeutic market @ Stargardt Disease Market Trends.
Motion sickness is a common condition experienced during travel, characterized by a disconnect between visual perception and the inner ear’s vestibular signals. Despite its widespread occurrence, there remains a notable absence of highly effective therapies specifically approved for this condition. Current management strategies employ a multidisciplinary approach combining both pharmacological and non-pharmacological interventions. The standard of care typically includes anticholinergics (particularly scopolamine transdermal patches), antihistamines (cyclizine, dimenhydrinate, promethazine, meclizine), and anti-emetic medications that aim to prevent or mitigate symptoms rather than address the underlying cause.
The current motion sickness treatment landscape is notably limited by partial efficacy and unwanted side effects associated with available options. Scopolamine, while considered the most effective and widely prescribed agent for motion sickness, comes with considerable drawbacks, including dry eyes and mouth, drowsiness, and tachycardia due to its non-selective anticholinergic properties. Many patients turn to complementary approaches, including behavioral modifications and natural remedies, which may offer modest relief for some individuals.
The motion sickness pharmaceutical pipeline shows promising developments that could significantly impact treatment paradigms. Defender Pharmaceuticals’ DPI-386, a low-dose intranasal scopolamine gel, represents a notable advancement with its rapid absorption and onset of action. However, despite successful clinical trials, the FDA issued a Complete Response Letter (CRL) to Defender Pharmaceuticals in January 2024, requiring further review for DPI-386.
Discover evolving trends in the Stargardt Disease therapeutic landscape @ Stargardt Disease Pipeline.
Additionally, Vanda Pharmaceuticals and Eli Lilly’s VLY-686 (tradipitant), a small NK-1 receptor antagonist designed to prevent vomiting, was anticipated to reach US market approval by 2025. However, the FDA declined to approve the NDA for tradipitant in September 2024, issuing a Complete Response Letter. Vanda has accepted the FDA’s invitation for a hearing to contest the decision, but the process has been delayed, and the hearing is not expected to occur before September 2025. These developments highlight the continuing challenge in bringing new motion sickness treatments to market, as the FDA has not approved a new medication for this condition in over forty years.
Discover recent advancements in the Stargardt Disease treatment landscape @ Stargardt Disease Recent Developments.
The motion sickness treatment marketplace faces several ongoing challenges, including the complex and poorly understood pathophysiology of the condition itself. The lack of established diagnostic and treatment guidelines results in therapeutic uncertainty and variable clinical approaches. Additionally, limited reimbursement structures create access barriers, with most treatments being available over the counter and lacking insurance coverage.
Looking ahead, the motion sickness market is poised for transformation through targeted pharmaceutical innovation. As understanding of vestibular-visual integration mechanisms improves, and novel drug delivery systems continue to evolve, patients can anticipate more effective and convenient treatment options. The expanding travel industry, increasing awareness of motion sensitivity disorders, and growing demand for better quality-of-life solutions during transportation collectively indicate strong growth potential for this therapeutic area, with significant opportunities for pharmaceutical companies developing advanced motion sickness medications.
Table of Contents
1. Key Insights
2. Report Introduction
3. Nausea and Vomiting Induced by Motion Sickness Market Overview at a Glance
4. Methodology of Nausea and Vomiting Induced by Motion Sickness Epidemiology and Market
5. Executive Summary of Nausea and Vomiting Induced by Motion Sickness
6. Key Events
7. Disease Background and Overview
8. Nausea and Vomiting Induced by Motion Sickness Patient Journey
9. Nausea and Vomiting Induced by Motion Sickness Epidemiology and Patient Population
10. Nausea and Vomiting Induced by Motion Sickness Emerging Drugs
11. Nausea and Vomiting Induced by Motion Sickness: Market Analysis
12. Key Opinion Leaders’ Views
13. SWOT Analysis
14. Nausea and Vomiting Induced by Motion Sickness Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
